Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test

Universitas Padjadjaran

Status: Completed

Conditions: Cervical Cancer

Treatments: Diagnostic Test: Cerviray AI

Study type: Observational

Funder types: Other

Identifiers

NCT06518070

OBGY-202405.01

Details and patient eligibility

About

Cervical cancer, primarily caused by Human Papilloma Virus (HPV), is a significant global health concern, ranking as the fourth most common cancer in women worldwide. In Indonesia, it stands as the second most frequent cancer among women. This study investigates the performance of Cerviray® AI and Cerviray® AI Evaluation, an artificial intelligence (AI) technology for diagnosing cervical cancer, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC) with the Visual Inspection with Acetic Acid (VIA) test.

Full description

The study involved 44 patients from various health centers in West Java Province. Cerviray® AI, Cerviray® AI Evaluation, and VIA tests were administered to high-risk women of childbearing age.

Enrollment: 44 patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• high-risk women of childbearing age who would be screened for cervical cancer (by Cerviray AI examination, Cerviray AI evaluation, and VIA test) at 1 clinic and other 4 health centers

Exclusion criteria

• incomplete data
• patient refusing to be examined
• patient refusing to participate in the study